Advertisement

World Journal of Surgery

, Volume 34, Issue 7, pp 1416–1426 | Cite as

Choice of Management of Southern Chinese BRCA Mutation Carriers

  • Ava KwongEmail author
  • Connie H. N. Wong
  • Catherine Shea
  • Dacita T. K. Suen
  • Catherine L. Y. Choi
Article

Abstract

Background

Mutations in the BRCA genes confer greater risk of developing breast, ovarian, and prostate cancer. Families carrying the mutation can have intensive surveillance and take preventative measures. This is the first report on the uptake of such interventions in Chinese mutation carriers residing in Asia.

Methods

Breast and ovarian cancer index patients and family members referred for genetic counselling and testing who are found to carry the BRCA mutations were included in this multicenter study.

Results

A total of 31 patients with breast and/or ovarian cancer were found to carry BRCA1 or BRCA2 mutations. Forty-one tested family members also carried the mutations. Of the females, 85.7% of the index patients opted for breast surveillance and 23.8% for prophylactic mastectomy. Of the family members, 82.4% chose breast surveillance and 17.7% had prophylactic mastectomy. The majority of index patients and family members preferred ovarian surveillance (84 and 82.4%). Amongst the index patients, 32% decided for prophylactic salpingo-oophorectomy; 17.6% of the family members who did not have history of ovarian cancer decided to have prophylactic salpingo-oophorectomy. All male index patients agreed to breast and prostate surveillance, including breast clinical examination and PSA monitoring. For those male family members found to be BRCA mutation carriers, 56.3% agreed to have breast surveillance and 66.7% agreed to have prostate surveillance. No index patient or family member agreed to any form of chemoprevention.

Conclusions

Chinese BRCA mutation carriers have a higher uptake of cancer surveillance than prophylactic surgery and have a lack of interest in the use of chemoprevention drugs.

Keywords

Breast Cancer Ovarian Cancer Genetic Counseling Mutation Carrier BRCA Mutation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The authors thank Dr. Ellen Li Charitable Foundation, Kerry Group Kuok Foundation Limited, and The Hong Kong Cancer Fund for their continual support of the work of the Hong Kong Hereditary and High Risk Breast Cancer Programme and Hong Kong Hereditary Breast Cancer Family Registry; Professor Jim M. Ford and Professor Dee West, Stanford University for their continual guidance; Dr. Annie Chu and Miss Elaine Tsui for assisting with the update of the registry database; and Dr. Edmond S.K. Ma, Dr. Chris L.P. Wong, Dr. W.K. Chan, and Dr. Fian Law and the team at the Department of Molecular Pathology, Hong Kong Sanatorium and Hospital for contributing to the laboratory work.

References

  1. 1.
    Antoniou A et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130CrossRefPubMedGoogle Scholar
  2. 2.
    King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643–646CrossRefPubMedGoogle Scholar
  3. 3.
    Claus EB et al (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77(11):2318–2324CrossRefPubMedGoogle Scholar
  4. 4.
    Ford D et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62(3):676–689CrossRefPubMedGoogle Scholar
  5. 5.
    Bollet MA et al (2007) Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first. Radiother Oncol 82(3):272–280CrossRefPubMedGoogle Scholar
  6. 6.
    Mohamad HB, Apffelstaedt JP (2008) Counseling for male BRCA mutation carriers: a review. Breast 17(5):441–450CrossRefPubMedGoogle Scholar
  7. 7.
    Kirchhoff T et al (2004) BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 10(9):2918–2921CrossRefPubMedGoogle Scholar
  8. 8.
    Rebbeck TR et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22(6):1055–1062CrossRefPubMedGoogle Scholar
  9. 9.
    Meijers-Heijboer H et al (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345(3):159–164CrossRefPubMedGoogle Scholar
  10. 10.
    Rebbeck TR et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346(21):1616–1622CrossRefPubMedGoogle Scholar
  11. 11.
    Kauff ND et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346(21):1609–1615CrossRefPubMedGoogle Scholar
  12. 12.
    Society of Gynecologic Oncologists Committee (2005) Society of gynecologic oncologists clinical practice committee statement on prophylactic salpingo-oophorectomy. Gynecol Oncol 98(2):179–181Google Scholar
  13. 13.
    Daly MB (2006) Tamoxifen in ductal carcinoma in situ. Semin Oncol 33(6):647–649CrossRefPubMedGoogle Scholar
  14. 14.
    Narod SA et al (2002) Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94(23):1773–1779PubMedGoogle Scholar
  15. 15.
    Vogel VG (2009) The NSABP study of tamoxifen and raloxifene (STAR) trial. Expert Rev Anticancer Ther 9(1):51–60CrossRefPubMedGoogle Scholar
  16. 16.
    Bermejo-Perez MJ, Marquez-Calderon S, Llanos-Mendez A (2007) Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int J Cancer 121(2):225–231CrossRefPubMedGoogle Scholar
  17. 17.
    Sakorafas GH (2003) The management of women at high risk for the development of breast cancer: risk estimation and preventative strategies. Cancer Treat Rev 29(2):79–89CrossRefPubMedGoogle Scholar
  18. 18.
    Fisher B et al (2005) Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 97(22):1652–1662CrossRefPubMedGoogle Scholar
  19. 19.
    Houssami N, Cuzick J, Dixon JM (2006) The prevention, detection, and management of breast cancer. Med J Aust 184(5):230–234PubMedGoogle Scholar
  20. 20.
    Cummings SR et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 281(23):2189–2197CrossRefPubMedGoogle Scholar
  21. 21.
    The reduction in risk of ovarian cancer associated with oral-contraceptive use. The cancer and steroid hormone study of the centers for disease control and the national institute of child health and human development. N Engl J Med 316(11):650–655 (1987)Google Scholar
  22. 22.
    Brown S et al (2009) Initial radiation experience evaluating early tolerance and toxicities in patients undergoing accelerated partial breast irradiation using the contura multi-lumen balloon breast brachytherapy catheter. Brachytherapy 8(2):227–233CrossRefPubMedGoogle Scholar
  23. 23.
    Burke W et al (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer genetics studies consortium. JAMA 277(12):997–1003CrossRefPubMedGoogle Scholar
  24. 24.
    Kriege M et al (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351(5):427–437CrossRefPubMedGoogle Scholar
  25. 25.
    Stoutjesdijk MJ et al (2001) Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 93(14):1095–1102CrossRefPubMedGoogle Scholar
  26. 26.
    Leach MO et al (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365(9473):1769–1778CrossRefPubMedGoogle Scholar
  27. 27.
    Warner E et al (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292(11):1317–1325CrossRefPubMedGoogle Scholar
  28. 28.
    National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 55(3 Pt 2):S4–S14 (1994)Google Scholar
  29. 29.
    Dorum A et al (1999) Prospectively detected cancer in familial breast/ovarian cancer screening. Acta Obstet Gynecol Scand 78(10):906–911CrossRefPubMedGoogle Scholar
  30. 30.
    Wainberg S, Husted J (2004) Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation. Cancer Epidemiol Biomarkers Prev 13(12):1989–1995PubMedGoogle Scholar
  31. 31.
    Domchek SM et al (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 7(3):223–229CrossRefPubMedGoogle Scholar
  32. 32.
    Metcalfe KA et al (2008) International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122(9):2017–2022CrossRefPubMedGoogle Scholar
  33. 33.
    Ford D et al (1994) Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet 343(8899):692–695CrossRefPubMedGoogle Scholar
  34. 34.
    Easton DF et al (1997) Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 61:120–128CrossRefPubMedGoogle Scholar
  35. 35.
    Struewing JP et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336(20):1401–1408CrossRefPubMedGoogle Scholar
  36. 36.
    Hopper JL et al (1999) Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian breast cancer family study. Cancer Epidemiol Biomarkers Prev 8(9):741–747PubMedGoogle Scholar
  37. 37.
    Podo F et al (2002) The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res 21(3 Suppl):115–124PubMedGoogle Scholar
  38. 38.
    Kauff ND et al (2008) Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26(8):1331–1337CrossRefPubMedGoogle Scholar
  39. 39.
    Fatouros M, Baltoyiannis G, Roukos DH (2008) The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 15(1):21–33CrossRefPubMedGoogle Scholar
  40. 40.
    Domchek SM, Stopfer JE, Rebbeck TR (2006) Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers. J Natl Compr Canc Netw 4(2):177–182PubMedGoogle Scholar
  41. 41.
    Milsom I, Odlind V (2008) Oral contraceptives give long-lasting protection against ovarian cancer. Use of oral contraceptives can explain reduced incidence of ovarian cancer in Sweden. Lakartidningen 105(10):715–716PubMedGoogle Scholar
  42. 42.
    Bonn D (2002) Prostate-cancer screening targets men with BRCA mutations. Lancet Oncol 3(12):714CrossRefPubMedGoogle Scholar
  43. 43.
    Giri VN et al (2007) Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol 178(5):1920–1924CrossRefPubMedGoogle Scholar
  44. 44.
    Basu SK et al (2008) Unilateral and bilateral breast cancer in women surviving pediatric Hodgkin’s disease. Int J Radiat Oncol Biol Phys 72(1):34–40PubMedGoogle Scholar
  45. 45.
    Kwong A et al (2008) Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family. Fam Cancer 7(2):125–133CrossRefPubMedGoogle Scholar
  46. 46.
    Lim YK et al (2007) Identification of novel BRCA large genomic rearrangements in Singapore Asian breast and ovarian patients with cancer. Clin Genet 71(4):331–342CrossRefPubMedGoogle Scholar
  47. 47.
    Song CG et al (2006) BRCA1 and BRCA2 gene mutations of familial breast cancer from Shanghai in China. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 23(1):27–31PubMedGoogle Scholar
  48. 48.
    Law TT et al (2009) Telephone pre-anaesthesia assessment for ambulatory breast surgery. Hong Kong Med J 15(3):179–182PubMedGoogle Scholar
  49. 49.
    Kriege M et al (2006) Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition. Cancer 106(11):2318–2326CrossRefPubMedGoogle Scholar
  50. 50.
    Choi DH et al (2004) Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol 22(9):1638–1645CrossRefPubMedGoogle Scholar
  51. 51.
    Gomez SL, France AM, Lee MM (2004) Socioeconomic status, immigration/acculturation, and ethnic variations in breast conserving surgery, San Francisco Bay area. Ethn Dis 14(1):134–140PubMedGoogle Scholar
  52. 52.
    Julian-Reynier CM et al (2001) Women’s attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer 92(4):959–968CrossRefPubMedGoogle Scholar
  53. 53.
    Suen D, Chow L, Kwong A (2008) Breast-conserving surgery in Hong Kong Chinese women. World J Surg 32(12):2549–2553CrossRefPubMedGoogle Scholar
  54. 54.
    Litton JK et al (2009) Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115(8):1598–1604CrossRefPubMedGoogle Scholar
  55. 55.
    Scheuer L et al (2002) Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20(5):1260–1268CrossRefPubMedGoogle Scholar
  56. 56.
    Meijers-Heijboer EJ et al (2000) Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 355(9220):2015–2020CrossRefPubMedGoogle Scholar
  57. 57.
    Lodder LN et al (2002) One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat 73(2):97–112CrossRefPubMedGoogle Scholar
  58. 58.
    Uyei A et al (2006) Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer 107(12):2745–2751CrossRefPubMedGoogle Scholar
  59. 59.
    Ray JA, Loescher LJ, Brewer M (2005) Risk-reduction surgery decisions in high-risk women seen for genetic counseling. J Genet Couns 14(6):473–484CrossRefPubMedGoogle Scholar
  60. 60.
    Botkin JR et al (2003) Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A 118A(3):201–209CrossRefPubMedGoogle Scholar
  61. 61.
    Stirling D et al (2005) Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system. J Clin Oncol 23(24):5588–5596CrossRefPubMedGoogle Scholar
  62. 62.
    Brekelmans CT et al (2001) Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 19(4):924–930PubMedGoogle Scholar
  63. 63.
    Liberman L (2004) Breast cancer screening with MRI–what are the data for patients at high risk? N Engl J Med 351(5):497–500CrossRefPubMedGoogle Scholar
  64. 64.
    Tabar L et al (2004) Number needed to screen: lives saved over 20 years of follow-up in mammographic screening. J Med Screen 11(3):126–129CrossRefPubMedGoogle Scholar
  65. 65.
    Warner E, Causer PA (2005) MRI surveillance for hereditary breast-cancer risk. Lancet 365(9473):1747–1749CrossRefPubMedGoogle Scholar
  66. 66.
    Robson ME, Offit K (2004) Breast MRI for women with hereditary cancer risk. JAMA 292(11):1368–1370CrossRefPubMedGoogle Scholar
  67. 67.
    Kerlikowske K, Brown JS, Grady DG (1992) Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol 80(4):700–707PubMedGoogle Scholar
  68. 68.
    Kwong A et al (2008) Breast cancer in Chinese women younger than age 40: are they different from their older counterparts? World J Surg 32:2554–2561CrossRefPubMedGoogle Scholar
  69. 69.
    Kwong A et al (2008) The acceptance and feasibility of breast cancer screening in the East. Breast 17(1):42–50CrossRefPubMedGoogle Scholar
  70. 70.
    Nagata C et al (2005) Mammographic density and the risk of breast cancer in Japanese women. Br J Cancer 92(12):2102–2106CrossRefPubMedGoogle Scholar
  71. 71.
    Ursin G et al (1999) Breast cancer and oral contraceptive use in Asian-American women. Am J Epidemiol 150(6):561–567PubMedGoogle Scholar
  72. 72.
    Haars G et al (2005) Measurements of breast density: no ratio for a ratio. Cancer Epidemiol Biomarkers Prev 14(11 Pt 1):2634–2640CrossRefPubMedGoogle Scholar
  73. 73.
    Buist DS et al (2004) Factors contributing to mammography failure in women aged 40–49 years. J Natl Cancer Inst 96(19):1432–1440CrossRefPubMedGoogle Scholar
  74. 74.
    Kuhl CK et al (2005) Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23(33):8469–8476CrossRefPubMedGoogle Scholar
  75. 75.
    Shah SK, Shah SK, Greatrex KV (2005) Current role of magnetic resonance imaging in breast imaging: a primer for the primary care physician. J Am Board Fam Pract 18(6):478–490CrossRefPubMedGoogle Scholar
  76. 76.
    Kwong A et al (2009) A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer. Breast Cancer Res Treat 117:683–686CrossRefPubMedGoogle Scholar
  77. 77.
    Plevritis SK et al (2006) Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 295(20):2374–2384CrossRefPubMedGoogle Scholar
  78. 78.
    Metcalfe KA et al (2005) The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Fam Cancer 4(2):97–103CrossRefPubMedGoogle Scholar
  79. 79.
    Foster C et al (2007) Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up. Br J Cancer 96(5):718–724CrossRefPubMedGoogle Scholar
  80. 80.
    Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62(1):145–158CrossRefPubMedGoogle Scholar
  81. 81.
    Kurian AW, Gong GD, Chun NM et al (2008) Performance of BRCA1/2 mutation prediction models in Asian Americans. J Clin Oncol 26(29):4752–4758CrossRefPubMedGoogle Scholar
  82. 82.
    Thirthagiri E et al (2008) Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer. Breast Cancer Res 10(4):R59CrossRefPubMedGoogle Scholar
  83. 83.
    Rao NY, Hu Z, Yu YM et al (2008) Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients. Breast Cancer Res Treat 116(3):563–570CrossRefPubMedGoogle Scholar
  84. 84.
    Brandberg Y et al (2008) Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol 26(24):3943–3949CrossRefPubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2010

Authors and Affiliations

  • Ava Kwong
    • 1
    • 2
    • 3
    • 4
    Email author
  • Connie H. N. Wong
    • 1
    • 3
  • Catherine Shea
    • 1
  • Dacita T. K. Suen
    • 1
    • 3
  • Catherine L. Y. Choi
    • 1
  1. 1.Division of Breast SurgeryThe University of Hong Kong Li Ka Shing Faculty of MedicineHong KongHong Kong
  2. 2.Cancer Genetics CentreHong Kong Sanatorium and HospitalHong KongHong Kong
  3. 3.The Hong Kong Hereditary Breast Cancer Family RegistryHong KongHong Kong
  4. 4.Department of SurgeryStanford UniversityStanfordUSA

Personalised recommendations